NO20074057L - 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer - Google Patents
2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorerInfo
- Publication number
- NO20074057L NO20074057L NO20074057A NO20074057A NO20074057L NO 20074057 L NO20074057 L NO 20074057L NO 20074057 A NO20074057 A NO 20074057A NO 20074057 A NO20074057 A NO 20074057A NO 20074057 L NO20074057 L NO 20074057L
- Authority
- NO
- Norway
- Prior art keywords
- diaminopyridopyrimidine
- derivatives
- mtor inhibitors
- nitrogen
- attached form
- Prior art date
Links
- 229940124302 mTOR inhibitor Drugs 0.000 title 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
- CMMSUVYMWKBPQK-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine-2,4-diamine Chemical class N1=CC=CC2=NC(N)=NC(N)=C21 CMMSUVYMWKBPQK-UHFFFAOYSA-N 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Forbindelser med formel I: og isomerer, salter, solvater, kjemisk beskyttede former og prodrugs derav, hvor én av X1, X2 og X3 er N og de andre er CH; RN1 og RN2 danner sammen med nitrogenatomet de er bundet til, en nitrogen-holdig, heterocyklisk ring som har fra 4 til 8 ringatomer; RN3 og RN4 danner sammen med nitrogenatomet de er bundet til, en nitrogen-holdig, heterocyklisk ring som har fra 4 til 8 ringatomer, og anvendelsen av disse ved behandling av sykdommer som lindres ved inhibering av mTOR.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65617805P | 2005-02-25 | 2005-02-25 | |
| GBGB0503961.5A GB0503961D0 (en) | 2005-02-25 | 2005-02-25 | Compounds |
| US74240305P | 2005-12-05 | 2005-12-05 | |
| PCT/GB2006/000671 WO2006090169A1 (en) | 2005-02-25 | 2006-02-24 | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20074057L true NO20074057L (no) | 2007-09-17 |
Family
ID=36282842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20074057A NO20074057L (no) | 2005-02-25 | 2007-08-07 | 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1871377A1 (no) |
| JP (1) | JP2008531538A (no) |
| KR (1) | KR20070113252A (no) |
| AU (1) | AU2006217744A1 (no) |
| CA (1) | CA2599212A1 (no) |
| IL (1) | IL184901A0 (no) |
| MX (1) | MX2007010401A (no) |
| NO (1) | NO20074057L (no) |
| WO (1) | WO2006090169A1 (no) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008543888A (ja) | 2005-06-24 | 2008-12-04 | ギリアード サイエンシーズ， インコーポレイテッド | ピリド（３，２−ｄ）ピリミジン、およびＣ型肝炎を治療するのに有用な医薬組成物 |
| US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
| AU2007287430B2 (en) * | 2006-08-23 | 2011-07-21 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors |
| TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| UA101676C2 (uk) | 2008-07-31 | 2013-04-25 | Дженентек, Инк. | Піримідинові сполуки, композиції і способи застосування |
| CA2733554A1 (en) * | 2008-08-18 | 2010-02-25 | Yale University | Mif modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| KR20110115160A (ko) * | 2009-02-12 | 2011-10-20 | 메르크 세로노 에스. 에이. | 2-모르폴리노-피리도〔3,2-ｄ〕피리미딘 |
| WO2010118207A1 (en) * | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| AU2010300925A1 (en) | 2009-09-30 | 2012-03-29 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
| EP2762142A1 (en) | 2009-10-30 | 2014-08-06 | ARIAD Pharmaceuticals, Inc. | Compositions for treating cancer |
| MX2012005463A (es) | 2009-11-12 | 2012-09-12 | Hoffmann La Roche | Compuestos de purina n/9 sustituida, composiciones y metodos de uso. |
| KR101447789B1 (ko) | 2009-11-12 | 2014-10-06 | 에프. 호프만-라 로슈 아게 | Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법 |
| WO2011067356A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Polymorphs of a mek inhibitor |
| WO2011067348A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
| PH12012501581A1 (en) | 2010-02-03 | 2012-10-22 | Signal Pharm Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| BR112012024585A2 (pt) | 2010-03-30 | 2016-05-31 | Novartis Ag | inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas |
| AU2011240735B2 (en) | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
| US20130096149A1 (en) | 2010-06-25 | 2013-04-18 | Novartis Ag | Heteroaryl compounds and compositions as protein kinase inhibitors |
| EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| HK1199068A1 (en) | 2011-08-03 | 2015-06-19 | 西格诺药品有限公司 | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| MX372736B (es) * | 2012-09-28 | 2020-06-19 | Cancer Research Tech Ltd | Inhibidores de azaquinazolina de la proteina quinasa c atipica. |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| CN103588792B (zh) * | 2013-03-04 | 2016-03-23 | 中国科学院上海药物研究所 | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 |
| BR112015026257B1 (pt) | 2013-04-17 | 2022-12-20 | Signal Pharmaceuticals, Llc | Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit |
| EP2986321A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| HK1221150A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用二氢吡嗪并-吡嗪类对癌症的治疗 |
| JP6382945B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| CN105339008A (zh) | 2013-04-17 | 2016-02-17 | 西格诺药品有限公司 | 用于治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯酰胺的组合疗法 |
| MX393164B (es) | 2013-04-17 | 2025-03-21 | Signal Pharm Llc | Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona. |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| RU2643361C2 (ru) * | 2013-09-30 | 2018-02-01 | Кореа Рисёч Инститьют Оф Кемикал Текнолоджи | Новые производные триазолопиразина и их применение |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| JOP20190257A1 (ar) | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
| IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| TW202208355A (zh) * | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| AU2022269034A1 (en) * | 2021-05-04 | 2023-11-16 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| CN115304600B (zh) * | 2022-09-29 | 2023-01-13 | 北京鑫开元医药科技有限公司 | mTOR抑制剂、制备方法及用途 |
-
2006
- 2006-02-24 JP JP2007556665A patent/JP2008531538A/ja active Pending
- 2006-02-24 WO PCT/GB2006/000671 patent/WO2006090169A1/en not_active Ceased
- 2006-02-24 KR KR1020077021848A patent/KR20070113252A/ko not_active Withdrawn
- 2006-02-24 CA CA002599212A patent/CA2599212A1/en not_active Abandoned
- 2006-02-24 AU AU2006217744A patent/AU2006217744A1/en not_active Abandoned
- 2006-02-24 MX MX2007010401A patent/MX2007010401A/es not_active Application Discontinuation
- 2006-02-24 EP EP06709898A patent/EP1871377A1/en not_active Withdrawn
-
2007
- 2007-07-29 IL IL184901A patent/IL184901A0/en unknown
- 2007-08-07 NO NO20074057A patent/NO20074057L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1871377A1 (en) | 2008-01-02 |
| KR20070113252A (ko) | 2007-11-28 |
| JP2008531538A (ja) | 2008-08-14 |
| WO2006090169A1 (en) | 2006-08-31 |
| MX2007010401A (es) | 2008-02-19 |
| IL184901A0 (en) | 2007-12-03 |
| AU2006217744A1 (en) | 2006-08-31 |
| CA2599212A1 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074057L (no) | 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| UA95972C2 (ru) | Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а | |
| TN2009000107A1 (en) | New sulfonamide derivatives as bradykinin antagonists | |
| NO20091889L (no) | Inhibitorer av spiroketon acetyl-CoA karboksylase | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| NO20082346L (no) | Hydrazonderivater og anvendelser derav | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
| DE602006007012D1 (de) | Pyridinderivate als dipeptedyl-peptidase-hemmer | |
| MX2009012283A (es) | Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1. | |
| NO20085385L (no) | Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav | |
| EA201101089A1 (ru) | Производные оксадиазола в качестве агонистов рецептора s1p1 | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| NZ599040A (en) | 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases | |
| TW200833675A (en) | Nicotinamide derivatives | |
| UA88329C2 (en) | Dna-pk inhibitors | |
| TW201129564A (en) | Diphenylpyrazolopyridine derivatives, preparation thereof and therapeutic use thereof | |
| NO20085269L (no) | 2-tioksantinderivater som fungerer som MPO-inhibitorer | |
| NO20091265L (no) | Pyrrolopyrazin som Syk-kinase inhibitor | |
| NO20081217L (no) | Nye benzotiazolonderivater | |
| MX2010006063A (es) | Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis. | |
| NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
| NO20073170L (no) | Kaspaseinhibitorer og anvendelse derav | |
| TW200728260A (en) | Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof | |
| MX2011011281A (es) | Compuesto de carbinol que tiene un enlazante heterociclico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |